ClinicalTrials.Veeva

Menu

Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer (RDG)

F

Fujian Medical University

Status

Completed

Conditions

Stomach Neoplasm
Robotic Surgery

Treatments

Procedure: Robotic Distal Gastrectomy
Procedure: Laparoscopic Distal Gastrectomy

Study type

Interventional

Funder types

Other

Identifiers

NCT03313700
2017-02

Details and patient eligibility

About

The purpose of this study is to explore the clinical outcomes of the robotic distal gastrectomy for patients with gastric adenocarcinoma(cT1-4a, N-/+, M0).

Full description

Robotic surgery has been developed with the aim of improving surgical quality and overcoming the limitations of conventional laparoscopy in the performance of complex mini-invasive procedures. The study is designed to explore the clinical outcomes of the robotic distal gastrectomy by comparing short- and long-term outcomes including financial cost of robotic and laparoscopic distal gastrectomy in the treatment of gastric adenocarcinoma (cT1-4a, N-/+, M0).

Enrollment

300 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age from over 18 to under 75 years
  2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
  3. cT1-4a(clinical stage tumor), N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
  4. expected to perform distal gastrectomy with D1+/D2 lymph node dissction to obtain R0 resection sugicall results.
  5. Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale
  6. ASA (American Society of Anesthesiology) class I to III
  7. Written informed consent

Exclusion criteria

  1. Women during pregnancy or breast-feeding
  2. Severe mental disorder
  3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
  4. History of previous gastric surgery (except ESD/EMR (Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection )for gastric cancer)
  5. Gastric multiple primary carcinoma
  6. Enlarged or bulky regional lymph node (diameter over 3cm)supported by preoperative imaging
  7. History of other malignant disease within the past 5 years
  8. History of previous neoadjuvant chemotherapy or radiotherapy
  9. History of unstable angina or myocardial infarction within the past 6 months
  10. History of cerebrovascular accident within the past 6 months
  11. History of continuous systematic administration of corticosteroids within 1 month
  12. Requirement of simultaneous surgery for other disease
  13. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
  14. FEV1<50% of the predicted values

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

300 participants in 2 patient groups

Robotic Distal Gastrectomy
Experimental group
Description:
Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
Treatment:
Procedure: Robotic Distal Gastrectomy
Laparoscopic Distal Gastrectomy
Active Comparator group
Description:
Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
Treatment:
Procedure: Laparoscopic Distal Gastrectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems